• Listen: JPM22 in review, Biogen's worsening fortunes, & the future of RNA drugs

    4 days ago - By STAT

    Was J.P. Morgan a drag? Is it time to give up on Aduhelm? And how many guitars is too many?
    We cover all that and more this week on “The Readout LOUD,” STAT's biotech podcast. First, STAT health tech correspondent Katie Palmer joins us to recap the J.P. Morgan Healthcare Conference. Then, we discuss the latest twist in Biogen's quest to expand the use of Aduhelm and what it means for the treatment of Alzheimer's disease. Finally, Arrakis Therapeutics CEO Michael Gilman calls in to explain how targeting RNA can treat disease and why the characters in “Dune” don't just shoot each other with...
    Read more ...